Abstract
Recurrence in the allograft and progression in other organs increase mortality after cardiac transplantation in AL amyloidosis. Survival may be improved after suppression of monoclonal light chain (LC) production following high dose melphalan and autologous stem cell transplantation (HDM/ASCT). However, because of high treatment related mortality, this tandem approach is restricted to few patients without significant extra-cardiac involvement. A diagnosis of systemic AL amyloidosis was established in a 45-year old patient with congestive heart failure related to restrictive cardiomyopathy, nephrotic syndrome, peripheral neuropathy, postural hypotension, macroglossia, and lambda LC monoclonal gammopathy. After melphalan and dexamethasone (M-Dex) therapy, which resulted in 80% reduction of serum free lambda LC, he underwent orthotopic cardiac transplantation. Two years later, he remains in a sustained hematologic remission, with no evidence of allograft or extra-cardiac amyloid accumulation. M-Dex should be considered as an alternative therapy in AL amyloid heart transplant recipients ineligible for HDM/ASCT.AL amyloidosis is a systemic disorder, caused by a monoclonal light chains (LC) producing clonal dyscrasia, that mainly affects the kidneys, heart, liver, and peripheral and autonomic nervous systems.1,2 Restrictive cardiomyopathy is a severe and common manifestation of AL amyloidosis, associated with a median survival of approximately 9 months and less than 6 months once congestive heart failure is present.3
Cardiac transplantation in AL amyloidosis3–10 remains controversial, because of organ shortage, recurrence of amyloid in the graft, and progression of systemic deposits. Encouraging results were recently obtained in few cases of AL amyloid cardiomyopathy, with sequential heart transplantation followed by high dose melphalan (HDM) therapy and autologous stem cell transplantation (ASCT). Providing remission of the underlying plasma cell disorder is achieved by HDM/ASCT, amyloid deposits do not recur in the allograft and extra-cardiac disease progression is halted, resulting in prolonged survival.10 However, because of high treatment–related mortality associated with HDM/ASCT, this procedure is applicable only to selected cases. We report here a patient with systemic AL amyloidosis with congestive heart failure and multiple organ involvement, whose condition dramatically improved after cardiac transplantation following sustained clonal remission induced by melphalan plus dexamethasone.
References
- Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003; 349:583-96. PubMedhttps://doi.org/10.1056/NEJMra023144Google Scholar
- Kyle RA, Morie AG, Greipp PR. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood. 1999; 93:1062-6. PubMedGoogle Scholar
- Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005; 112:2047-60. PubMedhttps://doi.org/10.1161/CIRCULATIONAHA.104.489187Google Scholar
- Conner R, Hosenpud JD, Norman DJ, Pantely GA, Cobanoglu A, Starr A. Heart transplantation for cardiac amyloidosis : successful one-year outcome despite recurrence of the disease. J Heart Transplant. 1988; 7:165-72. PubMedGoogle Scholar
- Valentine HA, Billingham ME. Recurrence of amyloid in a cardiac allograft four months after transplantation. J Heart Transplant. 1989; 8:337-41. PubMedGoogle Scholar
- Hosenpud JD, DeMarco T, Frazier Oh. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Circulation. 1991; 84:338-43. Google Scholar
- Dubrey SW, Burke MM, Khaghani A, Hawkins PN, Yacoub MH, Banner NR. Long term results of heart transplantation in patients with amyloid heart disease. Heart. 2001; 85:202-207. PubMedhttps://doi.org/10.1136/heart.85.2.202Google Scholar
- Dubrey SW, Burke MM, Hawkins PN, Banner NR. Cardiac transplantation for amyloid heart disease: The United Kingdom Experience. J Heart Lung Transplant. 2004; 23:42-1153. Google Scholar
- Kpodonu J, Massad MG, Caines A, Geha AS. Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant. 2005; 24:1763-5. PubMedhttps://doi.org/10.1016/j.healun.2004.08.025Google Scholar
- Gillmore JD, Goodman HJ, Lachmann HJ. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood. 2006; 107:1227-9. PubMedhttps://doi.org/10.1182/blood-2005-08-3253Google Scholar
- Novak L, Cook WJ, Herrera GA, Sanders PW. AL-amyloidosis is underdiagnosed in renal biopsies. Nephrol Dial Transplant. 2004; 19:3050-3. PubMedhttps://doi.org/10.1093/ndt/gfh503Google Scholar
- Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002; 99:4276-82. PubMedhttps://doi.org/10.1182/blood.V99.12.4276Google Scholar
- Skinner M, Sanchorawala V, Seldin DC. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004; 140:85-93. PubMedhttps://doi.org/10.7326/0003-4819-140-2-200401200-00008Google Scholar
- Palladini G, Perfetti V, Obici L. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004; 103:2936-8. PubMedhttps://doi.org/10.1182/blood-2003-08-2788Google Scholar
- Jaccard A, Moreau P, Leblond V. Autologous stem cell transplantation versus oral melphalan plus high-dose dexamethasone in patients with AL (primary) amyloidosis: results of a French randomized trial. N Engl J Med. 2007. Google Scholar
- Palladini G, Lavatelli F, Russo P. Circulating amyloidogenic free light chains and serum N-terminal natiruretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006; 107:3854-8. PubMedhttps://doi.org/10.1182/blood-2005-11-4385Google Scholar
- Gertz MA, Comenzo R, Falk RH. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis. Am J Hematol. 2005; 79:319-28. PubMedhttps://doi.org/10.1002/ajh.20381Google Scholar
- Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol. 2004; 125:681-700. PubMedhttps://doi.org/10.1111/j.1365-2141.2004.04970.xGoogle Scholar